Key facts
as of Sep 2026- Parabilis Medicines’s last known valuation is $920.0M (Jan 2026).
- It has raised $812.0M across 3 recorded rounds; the latest was Later Stage VC (Series F) ($305.0M) in Jan 2026.
- Notable investors include General Catalyst, Fidelity Management & Research Company, RA Capital Management, GV, ARCH Venture Partners — 38 tracked in total.
- 4 institutional filers report fund marks on Parabilis Medicines across 19 filings.
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 38 names
- ·Watchlist + deal alerts for Parabilis Medicines
Recorded secondary trades
No secondary trades in Parabilis Medicines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
4 filers · latest Jun 20264 SEC-registered funds reported 19 fair-value marks on Parabilis Medicines between Apr 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
3 roundsAbout Parabilis Medicines
Developer of cell-penetrating mini proteins (CPMPs) designed to target cancer-causing proteins inside cancer cells and neutralize them. The company develops a pipeline of ultra-tunable peptide therapeutics based on a proprietary platform that is engineered to modulate previously inaccessible biological targets, incorporates structure-guided design to optimize pharmacologic properties, and supports programs primarily in oncology and other indications, enabling biopharmaceutical researchers and healthcare providers to access alternative treatment options for patients with limited effective therapies.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2015
- Employees
- 176
- Website
- parabilismed.com/
- Ownership
- Privately Held (backing)